Physician profile
William D King
NPI 1891715892
$1,681.30
in general payments reported to CMS, 2019-2025
16 companies · $28.70 in 2025
The $28.70 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $737 · 2021: $295 · 2022: $87.31 · 2024: $14.66 · 2025: $28.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $43.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $43.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $548.80 | 2019-2022 | |
| Pfizer INC. | $267.45 | 2019-2025 | |
| Lilly USA, LLC | $190.59 | 2019-2025 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $133.67 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $94.36 | 2019-2021 | |
| Amarin Pharma, INC. | $83.04 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $80.04 | 2020-2021 | |
| Eisai INC. | $56.54 | 2020 | |
| Amgen INC. | $45.36 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $38.49 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $36.99 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.18 | 2020 | |
| Glaxosmithkline, LLC. | $24.76 | 2020 | |
| Mannkind Corporation | $20.64 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.66 | 2024 | Zoryve |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.